New Opdivo data show survival benefit in NSCLC
Abstracts released ahead of the American Society of Clinical Oncology (ASCO) meeting featured data from several studies of Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY), including overall survival data from Opdivo as first and second-line therapy for non-small cell lung cancer (NSCLC) and preliminary OS data in a study to treat glioblastoma (GBM).
The human IgG4 mAb against PD-1 led to a median overall survival of 9.2 months vs. 6 months for docetaxel (p=0.00025) as second-line therapy in the Phase III CheckMate -017 trial to treat advanced or metastatic squamous cell NSCLC. The data showed tumor PD-L1 status did not predict OS outcomes. Among the patients in the Opdivo arm, 7% experienced grade 3/4 adverse events vs. 55% in the docetaxel arm. ...